Melanovus Oncology is developing novel products for the treatment of advanced melanoma to make a difference in how it's treated worldwide.
Melanovus Oncology is a late stage pre-clinical company advancing first-in-class treatments for late stage melanoma, which is a serious disease and represents a significant unmet medical need with a $3B market potential in the US. We have an experienced management team operating under a capital efficient model. Phase I could begin in mid-2013. We are seeking $1 million to advance through IND application.